Allspring Global Investments Holdings LLC Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

Allspring Global Investments Holdings LLC lowered its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 31.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 204,603 shares of the medical equipment provider's stock after selling 92,626 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.09% of Hologic worth $14,678,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HOLX. Creative Planning boosted its holdings in Hologic by 16.6% during the 3rd quarter. Creative Planning now owns 25,430 shares of the medical equipment provider's stock worth $2,072,000 after acquiring an additional 3,617 shares during the last quarter. Swedbank AB boosted its holdings in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Bleakley Financial Group LLC boosted its holdings in Hologic by 23.9% during the 3rd quarter. Bleakley Financial Group LLC now owns 6,368 shares of the medical equipment provider's stock worth $519,000 after acquiring an additional 1,227 shares during the last quarter. Blue Trust Inc. boosted its holdings in Hologic by 37.0% during the 3rd quarter. Blue Trust Inc. now owns 7,118 shares of the medical equipment provider's stock worth $528,000 after acquiring an additional 1,923 shares during the last quarter. Finally, OLD National Bancorp IN purchased a new position in Hologic during the 3rd quarter worth $204,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HOLX. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price objective on the stock. UBS Group boosted their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Raymond James reissued an "outperform" rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Finally, Stephens reissued an "overweight" rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic has a consensus rating of "Moderate Buy" and an average price target of $85.77.

Hologic Price Performance

Shares of HOLX traded up $0.12 during midday trading on Thursday, hitting $64.32. 1,953,696 shares of the company traded hands, compared to its average volume of 2,481,100. The stock has a 50-day moving average of $70.31 and a 200-day moving average of $76.82. Hologic, Inc. has a one year low of $62.69 and a one year high of $84.67. The firm has a market cap of $14.43 billion, a P/E ratio of 20.29, a PEG ratio of 2.12 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.